Cluster Profile
1 Name Of Cluster Thane Pharma cluster
2 Place Thane
3 District Thane
4 State Maharashtra
5 No of firms (by type) 37 
6 No. of workers 1700 
7 Turnover(Rs in Million's) 1300million
8 Associations in cluster NA
9 Major products Aluminum Hydroxide Gel
Magnesium Hydroxide Paste
Metronidazole benzoate
Chlorozoxagone
Dicyclomine Hydrochloride
Phenobarbitone IP
Carbonil Iron
Vitamin B12 ZelatinTrituarate
Iron Polymaltose
Nitrazebam

10 Specific and relevant technical institutions (R&D, Testing Lab accredited) NA
11 Major markets Mumbai,
Thane,
Raigad,
Pune,
Tarapur
Latin America,
Mexico,
Pakistan,
Asian countries
, South Africa

12 Major problems/prospects Need for easy Finance to meet Revised GMP standards and increase exports.
Role of Banking Sector: It has been pointed that whenever a SSI account is categorized as Non-Performing Asset (NPA), the unit is immediately threatened to be put in DRT
The investment limit for plant and machinery in the small scale sector has been reduced from Rs. 3 crores to Rs. 1 croreNon-availability of Skilled manpower
The Small Scale units does not pay much more attention in improving their managerial skills Burden of Taxes
There are very few Small Scale units which export bulk drugs to the formulation units in abroad countries
The development of pharmaceutical sector is dependent on the support of Food & Drug Administration.
Technical Problems faced by the Cluster
Issues relating to WHO-GMP compliance have been a relatively major area of concern for the industry as a whole.
The international quality norms especially those related to exports is also a major area of concern.
Low investment in R&D
Small firms are finding it difficult to avail right information as regards market, finance, technical, Govt. procedures etc.
Need for Common Testing Laboratory
Lack of knowledge of Govt. rules and regulations
13 Data source and updated on NA